Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
23 mai 2024 17h05 HE
|
Compass Therapeutics
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lincoln, Compass Minerals, Exscientia, and Akero and Encourages Investors to Contact the Firm
16 mai 2024 22h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, and Compass Minerals and Encourages Investors to Contact the Firm
12 mai 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, Compass Minerals, and Malibu Boats and Encourages Investors to Contact the Firm
08 mai 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, Compass Minerals, and Malibu Boats and Encourages Investors to Contact the Firm
04 mai 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, and Compass Minerals and Encourages Investors to Contact the Firm
30 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
COMPASS MINERALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Compass Minerals International, Inc. and Encourages Investors to Contact the Firm
26 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
16 avr. 2024 08h00 HE
|
Compass Therapeutics
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a...
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
29 févr. 2024 08h00 HE
|
Compass Therapeutics
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
28 févr. 2024 08h00 HE
|
Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...